Next-Generation CAR-T Company Raises €130M on NASDAQ IPO

London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. 

Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M in three funding rounds. Today, the company has topped it off by closing its NASDAQ IPO with a total of $150M (€130M) raised.

The money will help the company accelerate the development of its next-generation CAR-T technology. CAR-T therapy is changing the way we treat cancer, but the technology is young and it still has some limitations. Autolus is working on a new generation of CAR-T cells that can be programmed to address different types of cancer.


For example, one of Autolus’ CAR-T cells is designed to reduce cytokine release syndrome, a severe inflammatory reaction CAR-Ts that is known to have killed patients in clinical trials with CAR-T cells. In Phase I trial run at UCL, the treatment showed similar efficacy to commercial CAR-T therapies and the patients experienced less severe cases of cytokine release syndrome.

The company has also developed two off-switch mechanisms, one for blood cancers and another for solid tumors, that can be incorporated into CAR-T cells to induce their destruction when side effects are too strong.

Another therapy being developed by Autolus is able to target T cell lymphoma, which is a big challenge given that if healthy T cells are eliminated along with tumoral T cells, the patients are left vulnerable to infections. Autolus has developed an approach that only kills cancerous T cells.

With all these improvements to CAR-T therapy, Autolus seems to be getting the attention of investors, who see the promise in a new, better generation of a technology that is changing the treatment of cancer. This has helped it quickly join the ranks of other biotechs working on improving CAR-T, such as Cellectis in France, which also incorporates off switches in its CAR-T cells; or Celyad in Belgium, which is engineering the CAR-T cells to avoid rejection when sourcing them from donors instead of from the patient.

Images via Shutterstock; Autolus




Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.